A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers.
Adult
Alleles
BRCA1 Protein
/ genetics
BRCA2 Protein
/ genetics
Breast Neoplasms
/ genetics
Female
Genetic Predisposition to Disease
/ genetics
Genome-Wide Association Study
/ methods
Genotype
Humans
Linkage Disequilibrium
Middle Aged
Mutation
Polymorphism, Single Nucleotide
Quantitative Trait Loci
/ genetics
Risk Factors
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
17 02 2021
17 02 2021
Historique:
received:
28
10
2019
accepted:
19
11
2020
entrez:
18
2
2021
pubmed:
19
2
2021
medline:
2
3
2021
Statut:
epublish
Résumé
Breast cancer (BC) risk for BRCA1 and BRCA2 mutation carriers varies by genetic and familial factors. About 50 common variants have been shown to modify BC risk for mutation carriers. All but three, were identified in general population studies. Other mutation carrier-specific susceptibility variants may exist but studies of mutation carriers have so far been underpowered. We conduct a novel case-only genome-wide association study comparing genotype frequencies between 60,212 general population BC cases and 13,007 cases with BRCA1 or BRCA2 mutations. We identify robust novel associations for 2 variants with BC for BRCA1 and 3 for BRCA2 mutation carriers, P < 10
Identifiants
pubmed: 33597508
doi: 10.1038/s41467-020-20496-3
pii: 10.1038/s41467-020-20496-3
pmc: PMC7890067
doi:
Substances chimiques
BRCA1 Protein
0
BRCA1 protein, human
0
BRCA2 Protein
0
BRCA2 protein, human
0
Types de publication
Journal Article
Multicenter Study
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
1078Subventions
Organisme : NCI NIH HHS
ID : U01 CA176726
Pays : United States
Organisme : Medical Research Council
ID : MR/N003284/1
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : P50 CA116201
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180868
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA050385
Pays : United States
Organisme : NCI NIH HHS
ID : UM1 CA164917
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA199277
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA179715
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA128931
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA156733
Pays : United States
Organisme : Cancer Research UK
ID : C1275/A19187
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C8221/A19170
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : UM1 CA164973
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA176785
Pays : United States
Organisme : CIHR
ID : CRN-87521
Pays : Canada
Organisme : NCI NIH HHS
ID : RC4 CA153828
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA142996
Pays : United States
Organisme : Cancer Research UK
ID : C1287/A10710
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : P50 CA125183
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA087969
Pays : United States
Organisme : Cancer Research UK
ID : 14136
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : UM1 CA164920
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA168524
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA161032
Pays : United States
Organisme : Cancer Research UK
ID : C5047/A8385
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : R01 CA097396
Pays : United States
Organisme : NCI NIH HHS
ID : UM1 CA176726
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002538
Pays : United States
Organisme : Cancer Research UK
ID : C1275/C22524
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C1287/A16563
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : R01 CA058860
Pays : United States
Organisme : Cancer Research UK
ID : C12292/A11174
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : U10 CA027469
Pays : United States
Organisme : Cancer Research UK
ID : C5047/A10692
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : K07 CA092044
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000124
Pays : United States
Organisme : Cancer Research UK
ID : 11174
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C490/A16561
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : P50 CA058223
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA100374
Pays : United States
Organisme : Medical Research Council
ID : 1000143
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C490/A10124
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : U01 CA116167
Pays : United States
Organisme : Cancer Research UK
ID : C5047/A8384
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA214545
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA128978
Pays : United States
Organisme : NCI NIH HHS
ID : U19 CA148537
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA051008
Pays : United States
Organisme : Medical Research Council
ID : G0401527
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C570/A16491
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : R01 CA116167
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA177150
Pays : United States
Organisme : Cancer Research UK
ID : C1275/A11699
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : R01 CA063464
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA037517
Pays : United States
Organisme : NIGMS NIH HHS
ID : P20 GM130423
Pays : United States
Organisme : NCI NIH HHS
ID : UM1 CA186107
Pays : United States
Organisme : Medical Research Council
ID : MR/M012190/1
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : R25 CA112486
Pays : United States
Organisme : Cancer Research UK
ID : C5047/A15007
Pays : United Kingdom
Organisme : Medical Research Council
ID : G1000143
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : N02CP65504
Pays : United States
Organisme : Department of Health
ID : IS-BRC-1215-20007
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : U01 CA063464
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA077398
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA054281
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA132839
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA068485
Pays : United States
Organisme : CIHR
ID : GPH-129344
Pays : Canada
Organisme : NCI NIH HHS
ID : U01 CA058860
Pays : United States
Organisme : Cancer Research UK
ID : 10118
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : U19 CA148112
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA098758
Pays : United States
Organisme : Intramural NIH HHS
ID : Z01 ES044005
Pays : United States
Organisme : NCI NIH HHS
ID : U19 CA148065
Pays : United States
Organisme : Cancer Research UK
ID : C1275/A15956
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C1281/A12014
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C1287/A11990
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C8197/A16565
Pays : United Kingdom
Organisme : Intramural NIH HHS
ID : Z01 ES049033
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA192393
Pays : United States
Organisme : Cancer Research UK
ID : C1287/A10118
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : U10 CA180822
Pays : United States
Organisme : NCI NIH HHS
ID : R37 CA054281
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA164973
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA140286
Pays : United States
Organisme : NCI NIH HHS
ID : N02CP11019
Pays : United States
Organisme : NIEHS NIH HHS
ID : P30 ES009089
Pays : United States
Investigateurs
Ophélie Bertrand
(O)
Sandrine Caputo
(S)
Anaïs Dupré
(A)
Marine Le Mentec
(M)
Muriel Belotti
(M)
Anne-Marie Birot
(AM)
Bruno Buecher
(B)
Emmanuelle Fourme
(E)
Marion Gauthier-Villars
(M)
Lisa Golmard
(L)
Claude Houdayer
(C)
Virginie Moncoutier
(V)
Antoine de Pauw
(A)
Claire Saule
(C)
Olga Sinilnikova
(O)
Sylvie Mazoyer
(S)
Francesca Damiola
(F)
Laure Barjhoux
(L)
Carole Verny-Pierre
(C)
Mélanie Léone
(M)
Nadia Boutry-Kryza
(N)
Alain Calender
(A)
Sophie Giraud
(S)
Olivier Caron
(O)
Marine Guillaud-Bataille
(M)
Brigitte Bressac-de-Paillerets
(B)
Yves- Jean Bignon
(YJ)
Nancy Uhrhammer
(N)
Christine Lasset
(C)
Valérie Bonadona
(V)
Pascaline Berthet
(P)
Dominique Vaur
(D)
Laurent Castera
(L)
Tetsuro Noguchi
(T)
Cornel Popovici
(C)
Hagay Sobol
(H)
Violaine Bourdon
(V)
Tetsuro Noguchi
(T)
Audrey Remenieras
(A)
Catherine Noguès
(C)
Isabelle Coupier
(I)
Pascal Pujol
(P)
Aurélie Dumont
(A)
Françoise Révillion
(F)
Claude Adenis
(C)
Danièle Muller
(D)
Emmanuelle Barouk-Simonet
(E)
Françoise Bonnet
(F)
Virginie Bubien
(V)
Nicolas Sevenet
(N)
Michel Longy
(M)
Christine Toulas
(C)
Rosine Guimbaud
(R)
Laurence Gladieff
(L)
Viviane Feillel
(V)
Dominique Leroux
(D)
Hélène Dreyfus
(H)
Christine Rebischung
(C)
Magalie Peysselon
(M)
Fanny Coron
(F)
Laurence Faivre
(L)
Amandine Baurand
(A)
Caroline Jacquot
(C)
Geoffrey Bertolone
(G)
Sarab Lizard
(S)
Fabienne Prieur
(F)
Marine Lebrun
(M)
Caroline Kientz
(C)
Sandra Fert Ferrer
(SF)
Véronique Mari
(V)
Laurence Vénat-Bouvet
(L)
Capucine Delnatte
(C)
Stéphane Bézieau
(S)
Isabelle Mortemousque
(I)
Florence Coulet
(F)
Chrystelle Colas
(C)
Florent Soubrier
(F)
Mathilde Warcoin
(M)
Johanna Sokolowska
(J)
Myriam Bronner
(M)
Marie-Agnès Collonge-Rame
(MA)
Alexandre Damette
(A)
Paul Gesta
(P)
Hakima Lallaoui
(H)
Jean Chiesa
(J)
Denise Molina-Gomes
(D)
Olivier Ingster
(O)
Helen Gregory
(H)
Zosia Miedzybrodzka
(Z)
Patrick J Morrison
(PJ)
Kai-Ren Ong
(KR)
Alan Donaldson
(A)
Mark T Rogers
(MT)
M John Kennedy
(MJ)
Mary E Porteous
(ME)
Carole Brewer
(C)
Rosemarie Davidson
(R)
Louise Izatt
(L)
Angela Brady
(A)
Julian Barwell
(J)
Julian Adlard
(J)
Claire Foo
(C)
Fiona Lalloo
(F)
Lucy E Side
(LE)
Jacqueline Eason
(J)
Alex Henderson
(A)
Lisa Walker
(L)
Rosalind A Eeles
(RA)
Jackie Cook
(J)
Katie Snape
(K)
Diana Eccles
(D)
Alex Murray
(A)
Emma McCann
(E)
Stephen Fox
(S)
Ian Campbell
(I)
Amanda Spurdle
(A)
Penny Webb
(P)
Anna de Fazio
(A)
Margaret Tassell
(M)
Judy Kirk
(J)
Geoff Lindeman
(G)
Melanie Price
(M)
Melissa Southey
(M)
Roger Milne
(R)
Sid Deb
(S)
David Bowtell
(D)
Annemieke H van der Hout
(AH)
Ans M W van den Ouweland
(AMW)
Arjen R Mensenkamp
(AR)
Carolien H M van Deurzen
(CHM)
Carolien M Kets
(CM)
Caroline Seynaeve
(C)
Christi J van Asperen
(CJ)
Cora M Aalfs
(CM)
Encarna B Gómez Garcia
(EB)
Flora E van Leeuwen
(FE)
G H de Bock
(GH)
Hanne E J Meijers-Heijboer
(HEJ)
Inge M Obdeijn
(IM)
J Margriet Collée
(JM)
J J P Gille
(JJP)
Jan C Oosterwijk
(JC)
Juul T Wijnen
(JT)
Lizet E van der Kolk
(LE)
Maartje J Hooning
(MJ)
Margreet G E M Ausems
(MGEM)
Marian J E Mourits
(MJE)
Marinus J Blok
(MJ)
Matti A Rookus
(MA)
Muriel A Adank
(MA)
Rob B van der Luijt
(RB)
T C T E F van Cronenburg
(TCTEF)
Carmen C van der Pol
(CC)
Nicola S Russell
(NS)
Sabine Siesling
(S)
Lucy Overbeek
(L)
R Wijnands
(R)
Judith L de Lange
(JL)
Christine Clarke
(C)
Dinny Graham
(D)
Mythily Sachchithananthan
(M)
Deborah Marsh
(D)
Rodney Scott
(R)
Robert Baxter
(R)
Desmond Yip
(D)
Jane Carpenter
(J)
Alison Davis
(A)
Nirmala Pathmanathan
(N)
Peter Simpson
(P)
Commentaires et corrections
Type : ErratumIn
Références
Ferlay, J. et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136, E359–E386 (2015).
pubmed: 25220842
doi: 10.1002/ijc.29210
Pharoah, P. D. P., Day, N. E., Duffy, S., Easton, D. F. & Ponder, B. A. J. Family history and the risk of breast cancer: a systematic review and meta-analysis. Int. J. Cancer 71, 800–809 (1997).
pubmed: 9180149
doi: 10.1002/(SICI)1097-0215(19970529)71:5<800::AID-IJC18>3.0.CO;2-B
Nelson, H. D. et al. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: a systematic review to update the U.S. Preventive Services Task Force recommendation. Ann. Intern. Med. 160, 255–266 (2014).
pubmed: 24366442
doi: 10.7326/M13-1684
Kuchenbaecker, K. B. et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 317, 2402–2416 (2017).
pubmed: 28632866
doi: 10.1001/jama.2017.7112
Antoniou, A. C. et al. Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum. Mol. Genet. 18, 4442–4456 (2009).
pubmed: 19656774
pmcid: 2782243
doi: 10.1093/hmg/ddp372
Antoniou, A. C. et al. A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor–negative breast cancer in the general population. Nat. Genet. 42, 885–892 (2010).
pubmed: 20852631
pmcid: 3130795
doi: 10.1038/ng.669
Michailidou, K. et al. Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat. Genet. 45, 353–361 (2013).
pubmed: 23535729
pmcid: 3771688
doi: 10.1038/ng.2563
Thomas, G. et al. A multi-stage genome-wide association in breast cancer identifies two novel risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nat. Genet. 41, 579–584 (2009).
pubmed: 19330030
pmcid: 2928646
doi: 10.1038/ng.353
Finucane, H. K. et al. Partitioning heritability by functional annotation using genome-wide association summary statistics. Nat. Genet. 47, 1228–1235 (2015).
pubmed: 26414678
pmcid: 4626285
doi: 10.1038/ng.3404
Garcia-Closas, M. et al. Genome-wide association studies identify four ER negative–specific breast cancer risk loci. Nat. Genet. 45, 392–398e2 (2013).
pubmed: 23535733
pmcid: 3771695
doi: 10.1038/ng.2561
Couch, F. J. et al. Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. Nat. Commun. 7, 11375 (2016).
Lin, W.-Y. et al. Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk. Hum. Mol. Genet 24, 285–298 (2015).
pubmed: 25168388
doi: 10.1093/hmg/ddu431
Milne, R. L. et al. Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium. Hum. Mol. Genet. 23, 6096–6111 (2014).
pubmed: 24943594
pmcid: 4204770
doi: 10.1093/hmg/ddu311
Haiman, C. A. et al. A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor–negative breast cancer. Nat. Genet. 43, 1210–1214 (2011).
pubmed: 22037553
pmcid: 3279120
doi: 10.1038/ng.985
Bojesen, S. E. et al. Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat. Genet. 45, 371–384.e2 (2013).
pubmed: 23535731
pmcid: 3670748
doi: 10.1038/ng.2566
Ghoussaini, M. et al. Evidence that the 5p12 variant rs10941679 confers susceptibility to estrogen-receptor-positive breast cancer through FGF10 and MRPS30 regulation. Am. J. Hum. Genet. 99, 903–911 (2016).
pubmed: 27640304
pmcid: 5065698
doi: 10.1016/j.ajhg.2016.07.017
Glubb, D. M. et al. Fine-scale mapping of the 5q11.2 breast cancer locus reveals at least three independent risk variants regulating MAP3K1. Am. J. Hum. Genet. 96, 5–20 (2015).
pubmed: 25529635
pmcid: 4289692
doi: 10.1016/j.ajhg.2014.11.009
Gaudet, M. M. et al. Identification of a BRCA2-Specific Modifier Locus at 6p24 Related to Breast Cancer Risk. PLoS Genet. 9, e1003173 (2013).
Siddiq, A. et al. A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. Hum. Mol. Genet. 21, 5373–5384 (2012).
pubmed: 22976474
pmcid: 3510753
doi: 10.1093/hmg/dds381
Dunning, A. M. et al. Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. Nat. Genet. 48, 374–386 (2016).
pubmed: 26928228
pmcid: 4938803
doi: 10.1038/ng.3521
Sawyer, E. et al. Genetic predisposition to in situ and invasive lobular carcinoma of the breast. PLoS Genet. 10, e1004285 (2014).
pubmed: 24743323
pmcid: 3990493
doi: 10.1371/journal.pgen.1004285
Easton, D. F. et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 447, 1087–1093 (2007).
pubmed: 17529967
pmcid: 2714974
doi: 10.1038/nature05887
Turnbull, C. et al. Genome-wide association study identifies five new breast cancer susceptibility loci. Nat. Genet. 42, 504–507 (2010).
pubmed: 20453838
pmcid: 3632836
doi: 10.1038/ng.586
Orr, N. et al. Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2. Hum. Mol. Genet. 24, 2966–2984 (2015).
pubmed: 25652398
pmcid: 4406292
doi: 10.1093/hmg/ddv035
Darabi, H. et al. Polymorphisms in a putative enhancer at the 10q21.2 breast cancer risk locus regulate NRBF2 expression. Am. J. Hum. Genet. 97, 22–34 (2015).
pubmed: 26073781
pmcid: 4572510
doi: 10.1016/j.ajhg.2015.05.002
Meyer, K. B. et al. Fine-scale mapping of the fgfr2 breast cancer risk locus: putative functional variants differentially bind FOXA1 and E2F1. Am. J. Hum. Genet. 93, 1046–1060 (2013).
pubmed: 24290378
pmcid: 3852923
doi: 10.1016/j.ajhg.2013.10.026
French, J. D. et al. Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers. Am. J. Hum. Genet. 92, 489–503 (2013).
pubmed: 23540573
pmcid: 3617380
doi: 10.1016/j.ajhg.2013.01.002
Zeng, C. et al. Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. Breast Cancer Res. 18, 64 (2016).
Ghoussaini, M. et al. Genome-wide association analysis identifies three new breast cancer susceptibility loci. Nat. Genet. 44, 312–318 (2012).
pubmed: 22267197
pmcid: 3653403
doi: 10.1038/ng.1049
Udler, M. S. et al. Fine scale mapping of the breast cancer 16q12 locus. Hum. Mol. Genet 19, 2507–2515 (2010).
pubmed: 20332101
pmcid: 2876886
doi: 10.1093/hmg/ddq122
Darabi, H. et al. Fine scale mapping of the 17q22 breast cancer locus using dense SNPs, genotyped within the Collaborative Oncological Gene-Environment Study (COGs). Sci. Rep. 6, 32512 (2016).
pubmed: 27600471
pmcid: 5013272
doi: 10.1038/srep32512
Long, J. et al. Genome-Wide Association Study in East Asians Identifies Novel Susceptibility Loci for Breast Cancer. PLOS Genet 8, e1002532 (2012).
pubmed: 22383897
pmcid: 3285588
doi: 10.1371/journal.pgen.1002532
Cai, Q. et al. Genome-wide association analysis in East Asians identifies breast cancer susceptibility loci at 1q32.1, 5q14.3 and 15q26.1. Nat. Genet. 46, 886–890 (2014).
pubmed: 25038754
pmcid: 4127632
doi: 10.1038/ng.3041
Long, J. et al. A Common Deletion in the APOBEC3 Genes and Breast Cancer Risk. J. Natl Cancer Inst. 105, 573–579 (2013).
pubmed: 23411593
pmcid: 3627644
doi: 10.1093/jnci/djt018
Michailidou, K. et al. Association analysis identifies 65 new breast cancer risk loci. Nature 551, 92–94 (2017).
pubmed: 29059683
pmcid: 5798588
doi: 10.1038/nature24284
Mavaddat, N. et al. Prediction of breast cancer risk based on profiling with common genetic variants. J. Natl. Cancer Inst. 107, djv036 (2015).
Pashayan, N., Morris, S., Gilbert, F. J. & Pharoah, P. D. P. Cost-effectiveness and benefit-to-harm ratio of risk-stratified screening for breast cancer: a life-table model. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2018.1901 (2018).
Mavaddat, N. et al. Polygenic risk scores for prediction of breast cancer and breast cancer subtypes. Am. J. Hum. Genet. 104, 21–34 (2019).
pubmed: 30554720
doi: 10.1016/j.ajhg.2018.11.002
Antoniou, A. C. et al. RAD51 135G→C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am. J. Hum. Genet. 81, 1186–1200 (2007).
pubmed: 17999359
pmcid: 2276351
doi: 10.1086/522611
Garcia-Closas, M. et al. Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLoS Genet. 4, e1000054 (2008).
pubmed: 18437204
pmcid: 2291027
doi: 10.1371/journal.pgen.1000054
Antoniou, A. C. et al. Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am. J. Hum. Genet. 82, 937–948 (2008).
pubmed: 18355772
pmcid: 2427217
doi: 10.1016/j.ajhg.2008.02.008
Silva, L. D. & Lakhani, S. R. Pathology of hereditary breast cancer. Mod. Pathol. 23, S46–S51 (2010).
pubmed: 20436502
doi: 10.1038/modpathol.2010.37
Antoniou, A. C. et al. Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum. Mol. Genet. 20, 3304–3321 (2011).
pubmed: 21593217
pmcid: 3652640
doi: 10.1093/hmg/ddr226
Antoniou, A. C. et al. Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers. Breast Cancer Res. 14, R33 (2012).
pubmed: 22348646
pmcid: 3496151
doi: 10.1186/bcr3121
Couch, F. J. et al. Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet. 9, e1003212 (2013).
Kuchenbaecker, K. B. et al. Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res. 16, 3416 (2014).
Lawrenson, K. et al. Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast–ovarian cancer susceptibility locus. Nat. Commun. 7, 12675 (2016).
Milne, R. L. et al. Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nat. Genet. 49, 1767–1778 (2017).
pubmed: 29058716
pmcid: 5808456
doi: 10.1038/ng.3785
Kuchenbaecker, K. B. et al. Evaluation of polygenic risk scores for breast and ovarian cancer risk prediction in BRCA1 and BRCA2 mutation carriers. J. Natl. Cancer Inst. 109, djw302 (2017).
Chenevix-Trench, G. et al. An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA). Breast Cancer Res. 9, 104 (2007).
pubmed: 17466083
pmcid: 1868919
doi: 10.1186/bcr1670
Pierce, B. L. & Ahsan, H. Case-only genome-wide interaction study of disease risk, prognosis and treatment. Genet. Epidemiol. 34, 7–15 (2010).
pubmed: 19434715
pmcid: 2861332
Ottman, R. Gene–environment interaction: definitions and study designs. Prev. Med. 25, 764–770 (1996).
pubmed: 8936580
pmcid: 2823480
doi: 10.1006/pmed.1996.0117
Andrieu, N. & Goldstein, A. M. Epidemiologic and genetic approaches in the study of gene-environment interaction: an overview of available methods. Epidemiol. Rev. 20, 137–147 (1998).
pubmed: 9919434
doi: 10.1093/oxfordjournals.epirev.a017976
Fachal, L. et al. Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. Nature genetics, 52, 56–73 (2020).
pubmed: 31911677
pmcid: 6974400
doi: 10.1038/s41588-019-0537-1
Whittemore, A. S. Assessing environmental modifiers of disease risk associated with rare mutations. Hum. Hered. 63, 134–143 (2007).
pubmed: 17283442
doi: 10.1159/000099185
CIMBA - Consortium of Investigators of Modifiers of BRCA1/2 —. http://cimba.ccge.medschl.cam.ac.uk/ (2017).
Turner, A. et al. MADD knock-down enhances doxorubicin and TRAIL induced apoptosis in breast cancer cells. PLoS ONE 8, e56817 (2013).
pubmed: 23457619
pmcid: 3574069
doi: 10.1371/journal.pone.0056817
Zheng, T., Wang, A., Hu, D. & Wang, Y. Molecular mechanisms of breast cancer metastasis by gene expression profile analysis. Mol. Med. Rep. 16, 4671–4677 (2017).
pubmed: 28791367
pmcid: 5647040
doi: 10.3892/mmr.2017.7157
Sharma, D. K., Bressler, K., Patel, H., Balasingam, N. & Thakor, N. Role of Eukaryotic initiation factors during cellular stress and cancer progression. J. Nucleic Acids 2016, 8235121 (2016).
HANNA, S. et al. StarD13 is a tumor suppressor in breast cancer that regulates cell motility and invasion. Int. J. Oncol. 44, 1499–1511 (2014).
pubmed: 24627003
pmcid: 4027929
doi: 10.3892/ijo.2014.2330
Piegorsch, W. W., Weinberg, C. R. & Taylor, J. A. Non-hierarchical logistic models and case-only designs for assessing susceptibility in population-based case-control studies. Stat. Med. 13, 153–162 (1994).
pubmed: 8122051
doi: 10.1002/sim.4780130206
Kulminski, A. M. Complex phenotypes and phenomenon of genome-wide inter-chromosomal linkage disequilibrium in the human genome. Exp. Gerontol. 46, 979–986 (2011).
pubmed: 21907271
doi: 10.1016/j.exger.2011.08.010
Escala-Garcia, M. et al. Genome-wide association study of germline variants and breast cancer-specific mortality. Br. J. Cancer 120, 647–657 (2019).
pubmed: 30787463
pmcid: 6461853
doi: 10.1038/s41416-019-0393-x
BCAC - The Breast Cancer Association Consortium —. http://bcac.ccge.medschl.cam.ac.uk/ (2017).
Amos, C. I. et al. The OncoArray Consortium: A Network for Understanding the Genetic Architecture of Common Cancers. Cancer Epidemiol. Biomark. Prev. Publ. Am. Assoc. Cancer Res. Cosponsored Am. Soc. Prev. Oncol. 26, 126–135 (2017).
doi: 10.1158/1055-9965.EPI-16-0106
Consortium, T. 1000 G. P. A global reference for human genetic variation. Nature 526, 68–74 (2015).
doi: 10.1038/nature15393
Delaneau, O., Marchini, J. & Zagury, J.-F. A linear complexity phasing method for thousands of genomes. Nat. Methods 9, 179–181 (2011).
pubmed: 22138821
doi: 10.1038/nmeth.1785
O’Connell, J. et al. A General approach for haplotype phasing across the full spectrum of relatedness. PLOS Genet. 10, e1004234 (2014).
pubmed: 24743097
pmcid: 3990520
doi: 10.1371/journal.pgen.1004234
Howie, B. N., Donnelly, P. & Marchini, J. A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. PLoS Genet. 5, e1000529 (2009).
Browning, B. L. & Browning, S. R. A unified approach to genotype imputation and haplotype-phase inference for large data sets of trios and unrelated individuals. Am. J. Hum. Genet. 84, 210–223 (2009).
pubmed: 19200528
pmcid: 2668004
doi: 10.1016/j.ajhg.2009.01.005
Hohenlohe, P. A., Bassham, S., Currey, M. & Cresko, W. A. Extensive linkage disequilibrium and parallel adaptive divergence across threespine stickleback genomes. Philos. Trans. R. Soc. B Biol. Sci. 367, 395–408 (2012).
doi: 10.1098/rstb.2011.0245
Umbach, D. M. & Weinberg, C. R. Designing and analysing case-control studies to exploit independence of genotype and exposure. Stat. Med. 16, 1731–1743 (1997).
pubmed: 9265696
doi: 10.1002/(SICI)1097-0258(19970815)16:15<1731::AID-SIM595>3.0.CO;2-S
Spurdle, A. B. et al. Refined histopathological predictors of BRCA1 and BRCA2mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. Breast Cancer Res. 16, 3419 (2014).
Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature, 490, 61–70 (2012).
Mermel, C. H. et al. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 12, R41 (2011).
pubmed: 21527027
pmcid: 3218867
doi: 10.1186/gb-2011-12-4-r41
GTEx Consortium. The Genotype-Tissue Expression (GTEx) project. Nat. Genet. 45, 580–585 (2013).
doi: 10.1038/ng.2653
Li, Q. et al. Integrative eQTL-based analyses reveal the biology of breast cancer risk loci. Cell 152, 633–641 (2013).
pubmed: 23374354
pmcid: 4165609
doi: 10.1016/j.cell.2012.12.034
Shabalin, A. A. Matrix eQTL: ultra fast eQTL analysis via large matrix operations. Bioinforma. Oxf. Engl. 28, 1353–1358 (2012).
doi: 10.1093/bioinformatics/bts163
Fullwood, M. J. et al. An oestrogen-receptor-alpha-bound human chromatin interactome. Nature 462, 58–64 (2009).
pubmed: 19890323
pmcid: 2774924
doi: 10.1038/nature08497
Corradin, O. et al. Combinatorial effects of multiple enhancer variants in linkage disequilibrium dictate levels of gene expression to confer susceptibility to common traits. Genome Res. 24, 1–13 (2014).
pubmed: 24196873
pmcid: 3875850
doi: 10.1101/gr.164079.113
He, B., Chen, C., Teng, L. & Tan, K. Global view of enhancer–promoter interactome in human cells. Proc. Natl Acad. Sci. USA 111, E2191–E2199 (2014).
pubmed: 24821768
pmcid: 4040567
doi: 10.1073/pnas.1320308111
Andersson, R. et al. An atlas of active enhancers across human cell types and tissues. Nature 507, 455–461 (2014).
pubmed: 24670763
pmcid: 5215096
doi: 10.1038/nature12787
Hnisz, D. et al. Super-enhancers in the control of cell identity and disease. Cell 155, 934–947 (2013).
pubmed: 24119843
doi: 10.1016/j.cell.2013.09.053
Dixon, J. R. et al. Integrative detection and analysis of structural variation in cancer genomes. Nat. Genet. 50, 1388–1398 (2018).
pubmed: 30202056
pmcid: 6301019
doi: 10.1038/s41588-018-0195-8
McLaren, W. et al. The ensembl variant effect predictor. Genome Biol. 17, 122 (2016).
pubmed: 27268795
pmcid: 4893825
doi: 10.1186/s13059-016-0974-4